Tech Center 1600 • Art Units: 1626
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18569721 | TREATMENT AND PREVENTION OF DEVELOPMENTAL DISORDERS AND MENTAL DISEASES | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, |
| 17570997 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | Final Rejection | The Regents of the University of California |
| 18421264 | R-MDMA FOR TREATMENT OF PAIN | Non-Final OA | Mind Medicine, Inc. |
| 18255341 | COMPOUNDS FOR THE TREATMENT OF SARS | Non-Final OA | Purdue Research Foundation |
| 18215286 | INHIBITORS OF TRIM33 AND METHODS OF USE | Non-Final OA | DANA-FARBER CANCER INSTITUTE, INC. |
| 17788916 | Acylsulfamide Compound and Pharmaceutical Use Therefor | Non-Final OA | Japan Tobacco Inc. |
| 18557612 | ALKYLSULFENYL THIOCARBONATES: PRECURSORS TO HYDROPERSULFIDES POTENTLY ATTENUATE OXIDATIVE STRESS | Non-Final OA | The Johns Hopkins University |
| 18257123 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | Final Rejection | AstraZeneca AB |
| 18668678 | ALLOSTERIC INHIBITOR OF WEE1 KINASE | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17758847 | Inhibitors of Glucose-6-phosphate Dehydrogenase and Uses Thereof | Non-Final OA | The Trustees of Princeton University |
| 18552453 | Ether-Linked Antiviral Compounds | Non-Final OA | Pfizer Inc. |
| 18023456 | CONVERSION OF A BIOLOGICALLY SILENT MIRNA BINDING SMALL MOLECULE TO AN MIRNA DEGRADER | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18735162 | INDOLINE COMPOUNDS FOR INHIBITING KIF18A | Non-Final OA | Volastra Therapeutics, Inc. |
| 18104364 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | Final Rejection | Kadmon Corporation, LLC |
| 18246263 | PIPERAZINE-BASED CATIONIC LIPIDS | Non-Final OA | TRANSLATE BIO, INC. |
| 17924877 | PROCESS FOR THE SYNTHESIS OF N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1- YLMETHYLPHENYL)-5-ISO-BUTYLTHIOPHENE-2-SULFONAMIDE | Non-Final OA | VICORE PHARMA AB |
| 18572399 | ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY | Non-Final OA | Erasca, Inc. |
| 17435663 | HYDROXYPHEOPHORBIDE COMPOUNDS, METHODS AND USES THEREOF | Non-Final OA | UNIVERSIDADE DO PORTO |
| 18367900 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | Non-Final OA | NEUROPRO THERAPEUTICS, INC. |
| 17783941 | COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | Non-Final OA | PTC THERAPEUTICS, INC. |
| 18277289 | COMPOUND FOR INHIBITING NONSENSE-MEDIATED MRNA DECAY | Final Rejection | RIBOTECH CO., LTD. |
| 17634593 | ENZYME INHIBITORS | Non-Final OA | KALVISTA PHARMACEUTICALS LIMITED |
| 17923030 | PHOTOCHEMICAL SYNTHESIS OF MARMYCIN ANALOGUES THROUGH A NEW PHOTOCHEMICAL REACTION INVOLVING CARBONYL COMPOUNDS | Non-Final OA | Bowling Green State University |
| 18270317 | SERIES OF PIPERIDINE-SUBSTITUTED BENZOIC ACID COMPOUNDS, AND USE THEREOF | Non-Final OA | SHANGHAI FOSUN PHARMACEUTICAL INDUSTRIAL DEVELOPMENT CO., LTD. |
| 18035033 | NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND | Non-Final OA | UPPTHERA |
| 18320048 | BENZYLAMINE OR BENZYL ALCOHOL DERIVATIVE AND USES THEREOF | Non-Final OA | SHENZHEN HYPERWAY PHARMACEUTICALS CO., LTD |
| 18198423 | CYCLOPROPENIUM COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE | Non-Final OA | FUNDACIÓ INSTITUT CATALÀ D'INVESTIGACIÓ QUÍMICA |
| 18316742 | PREPARATION OF TRIFAROTENE AND INTERMEDIATES AND POLYMORPHS THEREOF | Final Rejection | TARO PHARMACEUTICAL INDUSTRIES LTD. |
| 17780894 | PIPERIDINE-2,6-DIONE DERIVATIVES WHICH BIND TO CEREBLON, AND METHODS OF USE THEREOF | Final Rejection | Captor Therapeutics S.A. |
| 17789185 | COMPOSITIONS FOR USE IN THE INHIBITION OF DIHYDROOROTATE DEHYDROGENASE | Final Rejection | HENDRIX COLLEGE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy